QUESTLAB

Quest Laboratories Share Price

 

 

Start SIP in QUESTLAB

Start SIP
Quest Laboratories live price: ₹108.35. It opened at ₹107 vs previous close ₹107; intraday high/low: ₹110/₹107. The 50 & 200 DMA stand at ₹110.25/₹103.37.

Quest Laboratories Performance

  • Low
  • ₹107
  • High
  • ₹110
  • 52 Week Low
  • ₹75
  • 52 Week High
  • ₹140
  • Open Price₹107
  • Previous Close₹107
  • Volume2,400
  • 50 DMA₹110.25
  • 100 DMA₹104.66
  • 200 DMA₹103.37

Investment Returns

  • Over 1 Month + 5.71%
  • Over 3 Month + 25.99%
  • Over 6 Month + 12.86%
  • Over 1 Year -9.03%

Smart Investing Starts Here Start SIP with Quest Laboratories for Steady Growth!

Invest Now

Quest Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 13.1
  • PEG Ratio
  • -
  • Market Cap Cr
  • 178
  • P/B Ratio
  • 1.9
  • Average True Range
  • 6.52
  • EPS
  • 8.59
  • Dividend Yield
  • 0
  • MACD Signal
  • 3.8
  • RSI
  • 43.58
  • MFI
  • 63.84

Quest Laboratories Financials

Quest Laboratories Technicals

EMA & SMA

Current Price
₹108.35
+ 1.4 (1.31%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹115.97
  • 50 Day
  • ₹110.25
  • 100 Day
  • ₹104.66
  • 200 Day
  • ₹103.37

Resistance and Support

108.37 Pivot Speed
  • R3 112.63
  • R2 111.22
  • R1 109.78
  • S1 106.93
  • S2 105.52
  • S3 104.08

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Quest Laboratories Ltd has an operating revenue of Rs. 125.87 Cr. on a trailing 12-month basis. An annual revenue growth of 31% is outstanding, Pre-tax margin of 18% is great, ROE of 16% is good. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 10% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -15% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 90 which is a GREAT score indicating consistency in earnings, a RS Rating of 85 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 61 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Quest Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-13 Quarterly Results
2025-11-13 Quarterly Results & Others To consider other business matters.
2025-05-28 Audited Results
2025-01-27 Others To consider other business matters.
2024-11-14 Quarterly Results & Others To consider other business matters.

Quest Laboratories F&O

Quest Laboratories Shareholding Pattern

66.78%
0%
0.61%
28.36%
4.25%

About Quest Laboratories

  • NSE Symbol
  • QUESTLAB
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Anil Kumar Sabarwal
  • ISIN
  • INE0TNW01017

Similar Stocks to Quest Laboratories

Quest Laboratories FAQs

Quest Laboratories share price is ₹108 As on 11 March, 2026 | 04:37

The Market Cap of Quest Laboratories is ₹177.6 Cr As on 11 March, 2026 | 04:37

The P/E ratio of Quest Laboratories is 13.1 As on 11 March, 2026 | 04:37

The PB ratio of Quest Laboratories is 1.9 As on 11 March, 2026 | 04:37

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23